aTyr Pharma Stock Price

-0.26 (-2.54%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
aTyr Pharma Inc LIFE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.26 -2.54% 9.99 13:34:45
Open Price Low Price High Price Close Price Prev Close
10.54 9.86 10.64 10.25
Bid Price Ask Price Spread News
9.98 10.02 0.04 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,336 661,736 $ 10.18 $ 6,738,499 - 2.93 - 13.10
Last Trade Time Type Quantity Stock Price Currency
13:34:47 1 $ 10.00 USD


Draw Mode:

aTyr Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 262.69M 26.29M 24.05M $ 10.46M $ - -1.58 -5.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 4.80%

more financials information »

aTyr Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LIFE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.8813.109.7711.645,500,1330.111.11%
1 Month5.3813.105.159.4717,126,9784.6185.69%
3 Months4.8413.104.229.365,733,3505.15106.4%
6 Months4.5813.103.509.032,802,2545.41118.12%
1 Year3.7313.102.938.051,898,9436.26167.83%
3 Years11.218213.102.137.70799,036-1.23-10.95%
5 Years46.4190.94262.1310.44576,055-36.42-78.47%

aTyr Pharma Description

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.

Your Recent History
aTyr Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.